The utility of genomics and functional imaging to predict Irinotecan and Sunitinib pharmacokinetics and pharmacodynamics

利用基因组学和功能成像预测伊立替康和舒尼替尼药代动力学和药效学

• 批准号: nhmrc : 628564
• 负责人: A/Pr Guy Toner
• 金额: $ 54.39万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/utility-genomics-functional-pharmacokinetics-pharmacodynamics/80884
• 关键词: utility; genomics; functional; imaging; predict

Cancer patients have large differences in the way their liver breaks down anticancer drugs, leading to a poor tumor response or severe side effects. This project will be with 2 cancer drugs which can cause severe side effects. Patients will have special liver Xrays to check their liver function and have blood taken to look at DNA or genes important in drug breakdown and action. These genes and imaging may help identify patients at risk of severe toxicity or poor response and optimise drug use.

癌症患者的肝脏分解抗癌药物的方式存在很大差异，导致肿瘤反应差或严重的副作用。该项目将使用两种可能导致严重副作用的抗癌药物。患者将接受特殊的肝脏X光检查，以检查他们的肝功能，并抽血检查药物分解和作用中重要的DNA或基因。这些基因和成像可能有助于识别有严重毒性或反应不良风险的患者，并优化药物使用。